Journal of Child and Adolescent Psychopharmacology · 2009 · 70 citations · 29 references
MedicinePharmacologyPsychiatryChild PsychiatryNeuropharmacologyPsychopharmacologyAdolescent PharmacotherapyChild PsychopharmacologyDopaminergic PharmacologyPediatric Clinical TrialsPediatric PsychopharmacologyStimulant Therapy5-Hydroxytryptamine 1A Receptor AgonistsAdhd PharmacotherapyAdhd TreatmentChronic Tic DisorderDopamine D2-like ReceptorsPartial Agonist EfficacyPartial Agonist PotencyPediatric Obsessive-compulsive Disorder Pharmacotherapy
BACKGROUND: Primarily safe and efficacious treatments for chronic tic disorders are needed. Also needed are such treatments that target co-morbid conditions. Aripiprazole, a dopaminergic/serotonergic agent with partial agonist properties at the D2 dopamine receptor and 5-hydrdoxytryptamine 1A (5-HT(1A)) receptor and antagonist properties at the 5-HT(2A) receptor, holds promise in both regards. OBJECTIVE: This was an open-label, flexible-dose study to evaluate the safety of aripiprazole in children and adolescents with a primary diagnosis of a chronic tic disorder with/without co-morbid disorder(s). METHOD: Sixteen children (15 males) aged 8-17 years participated in the 6-week trial. Ratings for tic, obsessive compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), and side effects were administered weekly. Baseline and exit laboratory measures, electrocardiograms (ECGs), weight, and height were obtained. RESULTS: The average daily aripiprazole dose was 3.3 mg (range 1.25-7.5 mg). Significant pre-and posttreatment differences were ascertained for the Yale Global Tic Severity Scale motor (p < or = 0.0001), phonic (p < or = 0.0001), and total tic (p < or = 0.0001) scores. Results of other rating scales suggested significant improvements in co-morbid disorders as well, including OCD, ADHD, and depressive disorders. Although aripiprazole was well tolerated, increases in weight were found. CONCLUSION: In this preliminary open-label trial, aripiprazole was a well-tolerated treatment for tics and co-morbid OCD and ADHD symptoms. Improvements in co-morbid conditions may be secondary to tic reduction or to specific to aripiprazole therapy; however, further study is warranted.
29
Joan Kaufman, Boris Birmaher, David A. Brent et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 1997 · 10.2K citations · Full text
Salvador Hernández‐López, José Bargas, D. James Surmeier et al. · Journal of Neuroscience · 1997 · 495 citations · Full text
A Depression Rating Scale for Children
Elva Poznanski, Stephen C. Cook, Bernard J. Carroll · PEDIATRICS · 1979 · 395 citations